Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome.

Cell Rep 2015 Oct 1;13(2):277-89. Epub 2015 Oct 1.

IRIBHM, Université Libre de Bruxelles (ULB), Route de Lennik, 808-1070 Brussels, Belgium; WELBIO, Route de Lennik, 808-1070 Brussels, Belgium. Electronic address:

Little is known about how RNA editing operates in cancer. Transcriptome analysis of 68 normal and cancerous breast tissues revealed that the editing enzyme ADAR acts uniformly, on the same loci, across tissues. In controlled ADAR expression experiments, the editing frequency increased at all loci with ADAR expression levels according to the logistic model. Loci-specific "editabilities," i.e., propensities to be edited by ADAR, were quantifiable by fitting the logistic function to dose-response data. The editing frequency was increased in tumor cells in comparison to normal controls. Type I interferon response and ADAR DNA copy number together explained 53% of ADAR expression variance in breast cancers. ADAR silencing using small hairpin RNA lentivirus transduction in breast cancer cell lines led to less cell proliferation and more apoptosis. A-to-I editing is a pervasive, yet reproducible, source of variation that is globally controlled by 1q amplification and inflammation, both of which are highly prevalent among human cancers.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2015.09.032DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5326813PMC
October 2015
49 Reads

Publication Analysis

Top Keywords

adar expression
12
breast cancer
8
cancer transcriptome
8
editing frequency
8
rna editing
8
frequency increased
8
adar
7
editing
6
response adar
4
interferon response
4
type interferon
4
adar dna
4
"editabilities" propensities
4
copy number
4
53% adar
4
expression variance
4
explained 53%
4
number explained
4
controls type
4
dna copy
4

Altmetric Statistics

Similar Publications